Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856375 · ClinicalTrials.gov registry record · Phase 2
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00856375 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 83 participants.
The verdict
NCT00856375, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of NKTR-102 compares with irinotecan, a cancer drug that is approved for use in the US for treatment of patients with certain types of colorectal cancer.
Interventions
- DRUG irinotecan
- DRUG NKTR-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856375
The ClinicalTrials.gov registry entry for NCT00856375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which irinotecan is the first listed.
NCT00856375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00856375 about?
NCT00856375 is a clinical study titled "NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer". This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of NKTR-102 compares with irinotecan, a cancer drug that is approved for use in the US for treatment of...
What is the current status of trial NCT00856375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2008-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00856375?
The interventions under investigation include: irinotecan (DRUG), NKTR-102 (DRUG).
Who is sponsoring clinical trial NCT00856375?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.